Italia markets close in 8 hours 11 minutes

JNJ Jan 2025 200.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,17000,0000 (0,00%)
In data: 02:47PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,1700
Aperto0,2400
Denaro0,0000
Lettera0,0000
Prezzo d'esercizio200,00
Scadenza2025-01-17
Min-Max giorno0,1700 - 0,2400
Contratto - Min-MaxN/D
Volume3
Open InterestN/D
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA